List view / Grid view
15 November 2010 | By Citigate Dewe Rogerson
Dr Allen brings to arGEN-X more than 12 years of corporate and business development experience with small and large biotech companies...
12 November 2010 | By The Scott Partnership
Sage-N Research announced that the SBMRI, has implemented the Sage-N SORCERER Enterprise proteomics platform...
11 November 2010 | By Capitalbio Corporation
Roche Diagnostics and CapitalBio announced their intention to initiate a strategic partnership targeting molecular diagnostic applications...
11 November 2010 | By RTS Life Science
ONE OF the UK’S fastest growing engineering groups, Entologi, is to buy leading life science automation company, RTS Life Science.
11 November 2010 | By Citigate Dewe Rogerson
For the Development and Commercialisation of Anti-Cancer Agent CP-4126 in Asia and Rest of the World...
10 November 2010 | By The Scott Partnership
Speeding the advance of compounds to clinical trials and expanding options for drug delivery...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced Mass Frontier 7.0, the newest release of its small molecule structural elucidation software. The software simplifies the management, evaluation and interpretation of mass spectral data and can be used for metabolism, metabolomics, forensics, natural products, impurities and degradants…
10 November 2010 | By Citigate Dewe Rogerson
Algeta ASA announces that Dr. Lars Abrahmsén has been appointed as Senior Vice President, Protein Therapeutics...
9 November 2010 | By NG Online News
Senior executives from Eli Lilly, AstraZeneca, Johnson and Johnson & Pfizer to discuss the ROI for "non-surrogate" biomarkers, dose selection biomarkers and biomarkers of efficacy.
9 November 2010 | By Unilabs YBS
Unilabs YBS announce that David J Browne has joined as Business Development Manager...
8 November 2010 | By ISPE
ISPE, announced that Genentech’s ECP-1 Bacterial Manufacturing Facility is the overall winner...
8 November 2010 | By Wragge & Co LLP
Wragge & Co has boosted its IP capability with the appointment of a new partner...
AstraZeneca and Bristol-Myers Squibb Company today announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults. KOMBIGLYZE XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycaemic control across…
4 November 2010 | By The Scott Partnership
Enable Pharmaceutical Manufacturers to Perform Easy and Reliable Transmembrane Protein Characterization...
4 November 2010 | By kdm communications limited
JAX to distribute mouse models created using proprietary ZFN technology...
